Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.
暂无分享,去创建一个
[1] L. Neckers,et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.
[2] K. Plate,et al. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.
[3] A. Harris,et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[4] D. Mukhopadhyay,et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.
[5] K. Herrup,et al. The essential role of Cited2, a negative regulator for HIF-1α, in heart development and neurulation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[6] Erwin G. Van Meir,et al. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells , 2001, Gene Therapy.
[7] W. Kaelin,et al. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.
[8] T. Nose,et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.
[9] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[10] K. Plate,et al. Up-Regulation of Vascular Endothelial Growth Factor in Stromal Cells of Hemangioblastomas Is Correlated with Up-Regulation of the Transcription Factor HRF/HIF-2α , 1998 .
[11] G. Semenza,et al. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .
[12] Andrew L. Kung,et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.
[13] A. Koong,et al. Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.
[14] A. Giaccia,et al. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. , 2001, Cancer research.
[15] R. Strausberg,et al. Transcriptional response to hypoxia in human tumors. , 2001, Journal of the National Cancer Institute.
[16] Christopher J Schofield,et al. Hypoxia-inducible Factor (HIF) Asparagine Hydroxylase Is Identical to Factor Inhibiting HIF (FIH) and Is Related to the Cupin Structural Family* , 2002, The Journal of Biological Chemistry.
[17] D. Peet,et al. Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.
[18] H. Nishi,et al. Early Growth Response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. , 2002, Cancer research.
[19] G. Semenza,et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.
[20] K. Kinzler,et al. Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Louis,et al. Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis , 1993, Brain pathology.
[22] Erwin G. Van Meir,et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.
[23] L. Ellis,et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. , 1998, Cancer research.
[24] A. Szalay,et al. The p14ARF Tumor Suppressor Protein Facilitates Nucleolar Sequestration of Hypoxia-inducible Factor-1α (HIF-1α) and Inhibits HIF-1-mediated Transcription* , 2001, The Journal of Biological Chemistry.
[25] G. Semenza,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[26] G. Semenza,et al. Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.
[27] D. Carbone,et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.
[28] D. Mukhopadhyay,et al. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.
[29] Mennel Hd,et al. Mechanisms of angiogenesis in the brain , 2000 .
[30] M. Nagao,et al. Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α Subunit* , 1997, The Journal of Biological Chemistry.
[31] P. Ratcliffe,et al. Activation of the HIF pathway in cancer. , 2001, Current opinion in genetics & development.
[32] D. Hanahan,et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. , 1997, Cancer research.
[33] G. Fulci,et al. p53 and Brain Tumors: From Gene Mutations to Gene Therapy , 1998, Brain pathology.
[34] B. Vogelstein,et al. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[35] Michael I. Wilson,et al. C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.
[36] Erwin G. Van Meir. Cytokines and tumors of the central nervous system , 1995, Glia.
[37] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[38] Erwin G. Van Meir,et al. Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. , 2001, The American journal of pathology.
[39] E. Oldfield,et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.
[40] Yuichi Makino,et al. Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway* , 1999, The Journal of Biological Chemistry.
[41] P. Carmeliet,et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice , 2002, Nature Medicine.
[42] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[43] G. Semenza,et al. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. , 1999, Developmental biology.
[44] Erwin G. Van Meir,et al. Thrombospondins and tumor angiogenesis. , 2001, Trends in molecular medicine.
[45] E. Manseau,et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. , 2001, The American journal of pathology.
[46] Erwin G. Van Meir,et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.
[47] Yusuke Nakamura,et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis , 1997, Oncogene.
[48] W. Cavenee,et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. , 1999, Cancer research.
[49] C. Heldin,et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.
[50] G. Semenza,et al. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. , 2001, Trends in molecular medicine.
[51] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[52] G. Semenza,et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.
[53] J. Gleadle,et al. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. , 1997, Blood.
[54] T. Mikkelsen,et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. , 1996, Cancer research.
[55] S. Sakaki,et al. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. , 1999, Cancer research.
[56] D. O’Rourke,et al. Epidermal Growth Factor Receptor Transcriptionally UpRegulates Vascular Endothelial Growth Factor Expression in Human Glioblastoma Cells via a Pathway Involving Phosphatidylinositol 3 *-Kinase and Distinct from That Induced by Hypoxia 1 , 2000 .
[57] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[58] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[59] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[60] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[61] G. Reifenberger,et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.
[62] G. Semenza,et al. Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway* , 2002, The Journal of Biological Chemistry.
[63] Michael P. Myers,et al. PTEN controls tumor-induced angiogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[64] H. Dvorak,et al. VPF/VEGF and the angiogenic response. , 2000, Seminars in perinatology.
[65] F. Zindy,et al. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[66] Christopher J. Robinson,et al. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.
[67] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[68] G. Semenza,et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.
[69] L. Poellinger,et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of theCBP/p300 coactivator by the hypoxia‐induciblefactor‐1α , 1998, The EMBO journal.
[70] A. Giaccia,et al. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. , 1997, Blood.
[71] P. Vogt,et al. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[72] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[73] Yoichi Taya,et al. Regulation of p53 by Hypoxia: Dissociation of Transcriptional Repression and Apoptosis from p53-Dependent Transactivation , 2001, Molecular and Cellular Biology.
[74] Till Acker,et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.
[75] M. Gassmann,et al. Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. , 1998, Cancer research.
[76] T. Fojo,et al. p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* , 1998, The Journal of Biological Chemistry.
[77] P. Wesseling,et al. Early and Extensive Contribution of Pericytes/Vascular Smooth Muscle Cells to Microvascular Proliferation in Glioblastoma Multiforme: An Immuno‐light and Immuno‐electron Microscopic Study , 1995, Journal of neuropathology and experimental neurology.
[78] Erwin G. Van Meir,et al. Upregulation of Interleukin 8 by Oxygen-deprived Cells in Glioblastoma Suggests a Role in Leukocyte Activation, Chemotaxis, and Angiogenesis , 1997, The Journal of experimental medicine.
[79] M. Lopes. Angiogenesis in brain tumors , 2003, Microscopy research and technique.
[80] Erwin G. Van Meir,et al. Genetic instability leads to loss of both p53 alleles in a human glioblastoma , 1998, Oncogene.
[81] Erwin G. Van Meir,et al. Thrombospondin-1 Is Downregulated by Anoxia and Suppresses Tumorigenicity of Human Glioblastoma Cells , 2000, The Journal of experimental medicine.
[82] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[83] W. Cavenee,et al. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. , 2001, Cancer research.
[84] H. Augustin,et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.
[85] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[86] L. Huang,et al. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .
[87] Erwin G. Van Meir,et al. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma , 1999, Oncogene.
[88] W Arap,et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. , 1997, Cancer research.
[89] G. Semenza,et al. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. , 1996, Biochemical and biophysical research communications.
[90] G. Semenza,et al. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.
[91] T. Hunter,et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[92] A. Harris,et al. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway , 2001, British Journal of Cancer.
[93] Charles J. Sherr,et al. Nucleolar Arf sequesters Mdm2 and activates p53 , 1999, Nature Cell Biology.
[94] Andrius Kazlauskas,et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.
[95] M. Ivan,et al. The von Hippel-Lindau tumor suppressor protein. , 2001, Current opinion in genetics & development.
[96] K. Dameron,et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.
[97] Dian Feng,et al. Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.
[98] M R Paradis,et al. Tumors of the central nervous system. , 1998, The Veterinary clinics of North America. Equine practice.
[99] Erwin G. Van Meir,et al. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. , 2003, The American journal of pathology.
[100] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[101] D. Peet,et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. , 2002, Genes & development.
[102] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[103] Yuichi Makino,et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression , 2001, Nature.
[104] Till Acker,et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function , 2000, Oncogene.
[105] L. Cantley,et al. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[106] Erwin G. Van Meir,et al. Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.
[107] S. Bhattacharya,et al. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. , 1999, Genes & development.
[108] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[109] J. Schlessinger,et al. Signaling by Receptor Tyrosine Kinases , 1993 .
[110] G. Semenza,et al. HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.
[111] D. Scudiero,et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.
[112] M. Jaye,et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[113] A. Tomida,et al. Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia , 2001, Oncogene.
[114] A. Giaccia,et al. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. , 1996, Cancer research.
[115] A. Giaccia,et al. Hypoxia Links ATR and p53 through Replication Arrest , 2002, Molecular and Cellular Biology.
[116] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[117] J. Folkman,et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[118] C. Heldin,et al. Platelet‐derived growth factor in human glioma , 1995, Glia.
[119] G. Semenza,et al. HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.
[120] T. Veikkola,et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.
[121] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[122] G. Reifenberger,et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.
[123] Erwin G. Van Meir,et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. , 2002, Cancer research.